Aveo Pharmaceuticals IPO pricing delayed-underwriter

NEW YORK, March 10 (Reuters) - Cancer therapy company AVEO Pharmaceuticals Inc (AVEO.O) will delay the pricing of its initial public offering until Thursday after the close of the market, an underwriter said.

The underwriter declined to give a reason. The IPO was expected to price on Wednesday. The company hopes to sell 7 million shares for $13 to $15 each. (Reporting by Clare Baldwin; Editing by Gary Hill)